Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 2, 2006, Pages 408-415

  Konski, Andre ^a   Watkins Bruner, Deborah ^a   Feigenberg, Steven ^a   Hanlon, Alexandra ^a   Kulkarni, Sachin ^a   Beck, J Robert ^a   Horwitz, Eric M ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cost effectiveness; Intensity modulated radiation therapy; Prostate cancer

Indexed keywords

BIOCHEMISTRY; COST EFFECTIVENESS; HEALTH RISKS; PATIENT TREATMENT; RADIOTHERAPY;

HEALTH POLICY; INTENSITY-MODULATED RADIATION THERAPY; PROSTATE CANCER; SALVAGE THERAPY;

DECISION THEORY;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEATH; HEALTH CARE COST; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; SURVIVAL TIME; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY;

AGED; ANDROGEN ANTAGONISTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 33748305706     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.04.049     Document Type: Article

References (30)

1. Purdy J.A. 3D treatment planning and intensity-modulated radiation therapy. Oncology (Williston Park) 13 (1999) 155-168
2. Verhey L.J. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 9 (1999) 78-98
3. Young R., and Snyder B. IMRT (intensity modulated radiation therapy): Progress in technology and reimbursement. Radiol Manage 23 (2001) 20-30 passim; quiz 33-35
4. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
5. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
6. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: A practical guide. Med Decis Making 13 (1993) 322-338
7. Beck J.R., and Pauker S.G. The Markov process in medical prognosis. Med Decis Making 3 (1983) 419-458
8. Naimark D., Krahn M.D., Naglie G., et al. Primer on medical decision analysis: Part 5-Working with Markov processes. Med Decis Making 17 (1997) 152-159
9. Fleming C., Wasson J.H., Albertsen P.C., et al., Prostate Patient Outcomes Research Team. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269 (1993) 2650-2658
10. Hummel S., Paisley S., Morgan A., et al. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: A systematic review. Health Technol Assess 7 (2003) iii-x 1-157.
11. Scher H.I., Kelly W.M., Zhang Z.F., et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91 (1999) 244-251
12. Oefelein M.G., Agarwal P.K., and Resnick M.I. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 171 (2004) 1525-1528
13. Horwitz E.M., Vicini F.A., Ziaja E.L., et al., American Society of Therapeutic Radiology and Oncology. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys 41 (1998) 267-272
14. Chism D.B., Hanlon A.L., Horwitz E.M., et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 380-385
15. Tom E., and Schulman K.A. Mathematical models in decision analysis. Infect Control Hosp Epidemiol 18 (1997) 65-73
16. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M.M.A. (Ed). Economic evaluation in health care Vol. I (2001), Oxford University Press, Oxford 173-214
17. Lipscomb J., Weinstein M.C., and Torrance G.W. Time preference. In: Gold M., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine Vol. I (1996), Oxford University Press, New York 214-235
18. Piper N.Y., Kusada L., Lance R., et al. Adenocarcinoma of the prostate: An expensive way to die. Prostate Cancer Prostatic Dis 5 (2002) 164-166
19. Doubilet P., Begg C.B., and Weinstein M.C. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 5 (1985) 157-177
20. Pass T., and Goldstein L.P. A computerized aid for medical cost-effective analysis. [Abstract]. Med Decis Making 1 (1981) 465
21. The EuroQol Group. EuroQol-A new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
22. Shipley W.U., Lu J.D., Pilepich M.V., et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54 (2002) 1302-1310
23. Ubel P.A., Hirth R.A., Chernew M.E., et al. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 163 (2003) 1637-1641
24. Paliwal B.R. IMRT may be used to excess because of its higher reimbursement from Medicare. For the proposition. Med Phys 31 (2004) 1-2
25. Marchal C., Bensadoun R.J., Hasle E., et al. Intensity modulated radiotherapy (IMRT) in France: The boost of the national funding for the new expensive innovative technologies (STIC 2001 and 2002). Cancer Radiother 7 Suppl. 1 (2003) 44s-48s
26. Ruchlin H.S., and Pellissier J.M. An economic overview of prostate carcinoma. Cancer 92 (2001) 2796-2810
27. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 45 (1999) 1219-1225
28. Maughan R.L., Brambs B., Porter A.T., et al. The cost-effectiveness of mixed beam neutron-photon radiation therapy in the treatment of adenocarcinoma of the prostate. Strahlenther Onkol 175 Suppl. 2 (1999) 104-107
29. Van Den Brink M., Van Den Hout W.B., Stiggelbout A.M., et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: A study of the Dutch Colorectal Cancer Group. J Clin Oncol 22 (2004) 244-253
30. Golub R.M., Bennett C.L., Stinson T., et al. Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms. J Clin Oncol 22 (2004) 2430-2437